Landmark legislation in Italy: Provisions for the treatment of rare diseases and for the support of research and production of orphan drugs
FDA approves first drug to improve growth in children with most common form of Dwarfism
NICE creates new menu of treatment options for those suffering from depression
At the start of 2026, we identified five key pharmaceutical pricing and market access trends expecte...
EU GPL: A Shift Towards More Selective Incentives for Orphan Drug Manufacturers In March 2026, the ...
Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.